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Estimates indicate that around 16,000 new cases of cervical
cancer were diagnosed in 2014 in Brazil. This cancer is the
third most frequent in Brazil, the first in the North region,
and the fifth in the South region of the country.1 The Unified
Health System (SUS), the public health care system of Brazil,
has implemented several actions for qualifying cervical
cancer screening, but there are challenges to be overcome,
such as the large national territory and heterogeneous
resources from every site.2 Despite the efforts made by
SUS, the current cervical cancer screening has shown
many weaknesses. There is no doubt that regular screening
of appropriate women for cervical cancer with the cytopa-
thology test reduces mortality from cervical cancer.3 How-
ever, appropriate policy and program organization remain
essential to achieve a good balance between benefit and
harm of any screening program. The knowledge of the
potential of population-based cervical screening to reduce
the burden of cervical cancer in the population is doubtless.
However, as pointed out by Dillner et al,4 this knowledge has
not always been translated into effective national programs.
To be effective, cervical cancer screening should be per-
formed in an organized, population-based screening pro-
gram with comprehensive quality assurance covering all
steps in the screening process. An organized program should
include quality assurance in monitoring cervical cancer
screening performance. The European guidelines define
such a performance through achieving: (1) an invitation
coverage of at least 95% of the target women; (2) an exami-
nation coverage of at least 70% (85% is desirable); and (3) a
participation rate of at least 70% (85% is desirable).5
The current recommendations for the SUS establish the
cytology-based cervical cancer screening, conducted with a
three-year interval after two consecutive annual negative
exams. The target population for cervical cancer screening
comprised women aged 25 to 64 years, which represents
around 55 million Brazilian women.6 Although SUS is uni-
versal, 25% of all Brazilians have private health; therefore,
41millionwomen are dependent on the SUS as their health
care provider. In the last decade, SUS conducted 9 to 11
million cytological exams per year.7 If it maintains the
recommended age group and three-year interval preconized,
the SUS would be able to include 27 to 33 million women in
the screening program, reaching almost 70–85% women as
preconized for an organized population-based program for
cervical cancer screening.4
In their Historical Analysis of the Brazilian Cervical Cancer
Screening Program from 2006 to 2013, Costa et al8 observed
that the Pap test coverage rate in Brazil is below 70%. Data
from theMinistry of Health from2012 and 2013 showed that
around 50% of the cytological tests in Brazil were conducted
on an annual basis and only 10%within a three-year interval.
Also, around 20% of the tests were conducted onwomen less
than 25 years of age.9 Regarding data from 2013, out of total
8,951,266 cytological tests, only 78.7% were conducted in
women aged 25–64 years old. Around 16% of these testswere
conducted in young women, aged less than 25 years or even
younger than 20 years: it is well known that treatment
procedures related to cervical lesion could be associated
with a higher frequency of obstetric and neonatal morbidity.
Also, for 46.9% of women, the interval since the last test was
one year or less, and only 9.4% followed the frequency
recommended in the Brazilian Cervical Cancer Screening
Guidelines.10
These data about Brazil present some regional variability,
but the general pattern tends to be homogeneous. An evalu-
ation of the cervical of the cancer screening program in
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Campinas, a more economically developed region, showed
63.7% of the tests exceeded the parameters defined in SUS
Guidelines, characterizing opportunistic screening, that is,
most women have their cytological test when seeking health
care for reasons other than cervical cancer screening.11 A
similar analysis for the municipality of Amparo showed that,
between 2001 and 2007, 61.2% to 65.5% of cytological tests
were conducted in excess, with a great number of women
under the recommended age.12 Although there was a de-
crease of 36% in invasive cervical cancer (with a significant
increment of stage I compared with advanced disease) in the
Hospital daMulher Professor Doutor José Aristodemo Pinotti
at Campinas StateUniversity, located in Campinas, from2006
to 2013, cervical cancer screening remains largely opportu-
nistic even in this region.13 Although it is an arduous and
complex task, Brazil could organize the cervical cancer
screening program through the use of SUS card.
Nonetheless, these efforts would bring little improvement
if the cytology quality is not assessed. Tobias et al,14 in the
article entitled “Quality indicators of cervical cytopathology
exams of public service in Minas Gerais State, Brazil,” indi-
cated the need to evaluate the performance of cytopathology
laboratories that provide services to the SUS. The authors
collected their data from the Cervical Cancer Information
System (SISCOLO). According to Costa et al,8 the SISCOLO is
an important tool for improving the Brazilian opportunistic
cervical cancer program, as it contains a significant amount
of data regarding Pap smear tests that can be used to
calculate quality indicators. Through these data, it is possible
to identify fragilities and strengths and to evaluate indicators
to adjust the course of action.
Tobias et al14 concluded that most of the laboratories
that provides service for SUS in the state of Minas Gerais
presented quality indicators outside the parameters recom-
mended by the Ministry of Health. Those findings are not
restricted to Minas Gerais state. Costa et al8 also observed
that the index of positivity was maintained at levels below
those indicated by international standards in all the states
in Brazil. They observed that the prevalence of cell alter-
ation, which characterizes the sensitivity of the screening
process for detecting lesions, was below those recom-
mended by the Brazilian guidelines (3–10%). They also
pointed out that these indexes are significantly below those
observed in developed countries, which have already
achieved control of cervical cancer incidence, such as
Norway (4.9%)15 or the USA (6.8%).16 Costa et al8 also found
that, although there was an increased rate of rejected exams
from 2009 to 2013, they observed very low frequencies of
unsatisfactory cases over the study period, which partially
contradicts the low rate of positive cases. In Brazil, the
prevalence rates of cytological results with alteration vary
significantly with the region, probably due to the cytologi-
cal test quality variability.17 The cytological test for cervical
cancer screening is a procedure that depends on the actions
of health care professionals and, therefore, shows high
performance variability.
Franco et al18 evaluated factors associated with false-
negative cervical cytopathological results. They found that
a small number of isolated atypical cells, present only in part
of the smear, and the presence of blood and inflammatory
process are frequently associated with false negative results
in cytological smear. These factors are largely related to the
collection conditions; therefore, the lesion cannot be ade-
quately represented in the Pap smear. Among the complex
chain of events in a cytology screening program, there are
important steps beyond the collection and processing of the
sample in the laboratory. Costa et al8 observed that the
percentage of rejected tests significantly increased in recent
years (2010–2013). Part of these results is explained by the
lack of care in handling, transportation and identification of
samples, which underscores the importance of focusing not
only on sample collection but also on all of the steps between
sample collection and sample analysis. Another important
pre-analytical indicator is the presence of epithelial cells
from the transformation zone (TZ): although the results
showed that the percentage of TZ cells was close to the
Brazilian National Cancer Institute reference value, it signifi-
cantly decreased over the years, whichmay be a consequence
of problems related to sample collection.
According to European guidelines for quality assurance in
cervical cancer screening, revised in 2015, the HPV primary
testing is suitable in an organized, population-based pro-
gram for cervical cancer screening. This statement has the
highest level of scientific evidence and this intervention is
strongly recommended.5 Currently, the understanding is
that there is necessary infrastructure to exploit the poten-
tial of HPV-based screening for improved cost-efficiency
within organized invitational screening programs.4 Addi-
tionally, the compliance with surveillance and optimal
management of HPV-positive women after primary HPV
screening is of key importance.19 Despite the advantage of
the DNA-HPV tests in achieving high laboratory quality
control and reproducibility, an organized screening is still
necessary.
Tobias et al14 data seriously highlight the need for educa-
tion activities involving all levels of health care agents to
improve the national cervical cancer screening program. As
long as the distance between the knowledge of the benefit of
the effective organized programs and the opportunistic
national program persists in Brazil, any effort to improve
the quality of any screening method, either cytological or
HPV detection, is unlikely to significantly impact mortality
from cervical cancer.
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